Luminex Corporation LMNX recently announced preliminary results for fourth-quarter 2018, wherein the top line surpassed the Zacks Consensus Estimate.
Revenues are anticipated to total $81 million, way above the Zacks Consensus Estimate of $77.9 million.
The company is scheduled to release full financial results on Feb 4.
Luminex’s fourth-quarter preliminary results seem to impress investors. The Zacks Rank #3 (Hold) stock rose 2.2% to $24.24 at close after the release of the results. If the company manages to outpace the Zacks Consensus Estimate in the fourth quarter, it will mark the first beat since the last reported quarter.
Over the past year, the stock has rallied 16.8% compared with the industry’s 0.4% rise. The current level also compares favorably with the S&P 500 index’s 7.1% decline.
Luminex Corporation Price and Consensus
Luminex Corporation Price and Consensus | Luminex Corporation Quote
Total Licensed Technologies Group revenues grew 23% year over year to more than $41 million. Total MDx revenues of approximately $39 million declined 11% year over year. Excluding the departure of LabCorp, total MDx revenues increased by approximately 21% year over year.
On a full-year basis, Luminex expects revenues to exceed $315 million, near the high end of the previous guidance of $310-$316 million. Notably, the figure comes above the Zacks Consensus Estimate of $312.6 million.
Per management, total Licensed Technologies Group revenues of $149 million grew 5% year over year. Total MDx revenues of approximately $164 million inched up 1% year over year. Excluding the departure of LabCorp, total MDx revenues were up approximately 13% on a year-over-year basis.
For 2019, Luminex expects revenues within $337-$343 million. The Zacks Consensus Estimate is pegged at $332.5 million, below the guided range.
Notably, the guidance includes contributions from the flow cytometry business purchased from MilliporeSigma.
A few better-ranked stocks in the broader medical space are Veeva Systems Inc VEEV, Penumbra, Inc. PEN and OPKO Health, Inc OPK. While, Veeva Systems and OPKO Health sport a Zacks Rank #1 (Strong Buy), Penumbra carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Veeva Systems’ long-term earnings growth rate is projected at 19.5%.
Penumbra has a long-term earnings growth rate of 20%.
OPKO Health’s long-term earnings growth rate is projected at 12%.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
OPKO Health, Inc. (OPK) : Free Stock Analysis Report
Luminex Corporation (LMNX) : Free Stock Analysis Report
Penumbra, Inc. (PEN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research